enzastaurin has been researched along with Recrudescence in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dreyling, M; Hartmann, E; Hutter, G; Rosenwald, A; Weinkauf, M; Zimmermann, Y | 1 |
| Buckner, JC; Galanis, E | 1 |
| Abonour, R; Anderson, KC; Desaiah, D; Ghobrial, IM; Harris, BN; Laubach, JP; Munshi, NC; Myrand, SP; Porter, NM; Richardson, PG; Schlossman, RL; Shi, P; Wooldridge, JE | 1 |
| Bian, Y; Boye, M; Day, JM; Duvic, M; Hamid, O; Kim, YH; Kuzel, TM; Lin, B; Mark, LA; Musiek, A; Pinter-Brown, L; Porcu, P; Querfeld, C; Rook, AH; Rosen, ST | 1 |
| Aster, JC; Cruz, JC; Darstein, C; de Vos, S; Enas, N; Flynn, PJ; Goldberg, SL; Kahl, BS; Kutok, JL; LaCasce, A; Laughlin, M; Musib, L; Neuberg, D; Robertson, MJ; Rowland, K; Savage, KJ; Shipp, MA; Slapak, CA; Thornton, D; Vose, JM | 1 |
| Cartron, G; Dreyling, M; Grigg, A; Kluin-Nelemans, HC; Milpied, N; Morschhauser, F; Pezzutto, A; Pfreundschuh, M; Raemaekers, J; Reyes, F; Seymour, JF; Spencer, A; Tilly, H; van 't Veer, MB; Wolf, M | 1 |
4 trial(s) available for enzastaurin and Recrudescence
| Article | Year |
|---|---|
A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Multiple Myeloma; Pyrazines; Recurrence; Time Factors | 2011 |
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Hyperkalemia; Indoles; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Recurrence; Sezary Syndrome; Skin Neoplasms; Treatment Outcome | 2011 |
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Immunohistochemistry; Indoles; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Recurrence | 2007 |
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Recurrence; Survival Analysis; Treatment Outcome | 2008 |
2 other study(ies) available for enzastaurin and Recrudescence
| Article | Year |
|---|---|
Combined RNA-expression and 2D-PAGE-screening identifies comprehensive interaction networks affected after bortezomib or enzastaurin exposure of mantle cell lymphoma.
Topics: Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Electrophoresis, Gel, Two-Dimensional; Gene Expression Profiling; High-Throughput Screening Assays; Humans; Indoles; Lymphoma, Mantle-Cell; Prognosis; Protease Inhibitors; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Recurrence | 2010 |
Enzastaurin in the treatment of recurrent glioblastoma: a promise that did not materialize.
Topics: Brain Neoplasms; Clinical Trials, Phase III as Topic; Glioblastoma; Humans; Indoles; Protein Kinase C; Protein Kinase C beta; Recurrence; Vascular Endothelial Growth Factor Receptor-2 | 2010 |